The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Association of excision repair cross-complementation group 1 (ERCC1) gene expression (GE) with outcome in stage II-III esophageal adenocarcinoma (EA) patients treated with preoperative platinum-based chemoradiation (CRT) in a phase II cooperative group study (SWOG S0356).
P. O. Bohanes
No relevant relationships to disclose
B. H. Goldman
No relevant relationships to disclose
L. P. Leichman
No relevant relationships to disclose
C. D. Blanke
Consultant or Advisory Role - Sanofi
S. Iqbal
Consultant or Advisory Role - Sanofi
C. R. Thomas
No relevant relationships to disclose
C. L. Corless
No relevant relationships to disclose
K. G. Billingsley
No relevant relationships to disclose
K. D. Danenberg
Employment or Leadership Position - Response Genetics
W. Zhang
No relevant relationships to disclose
J. K. Benedetti
No relevant relationships to disclose
P. J. Gold
No relevant relationships to disclose
H. Lenz
Stock Ownership - Response Genetics